Lamkin Clinic brings EXOMIND brain stimulation therapy to Oklahoma for depression care

The Lamkin Clinic has emerged as one of the first healthcare centers in Oklahoma to adopt EXOMIND, an FDA-cleared, noninvasive brain stimulation treatment designed to relieve depression and improve mental wellness. The Edmond-based clinic, known for its integrative and functional medicine approach, announced that the therapy will now be offered alongside its existing suite of holistic health treatments. This marks a significant milestone in the clinic’s mission to provide medication-free solutions for chronic mental health conditions that often resist traditional pharmaceutical therapies.

How does EXOMIND therapy work to improve depression and emotional regulation outcomes?

EXOMIND operates using targeted magnetic pulses to stimulate or suppress neural activity in specific brain regions associated with emotional regulation, cognition, and impulse control. The device applies these pulses through an applicator placed on the scalp, delivering low-intensity electromagnetic stimulation without pain or anesthesia. The clinic reported that patients undergoing EXOMIND sessions frequently experience better sleep quality, enhanced energy levels, and greater emotional resilience—three areas commonly disrupted by mood disorders.

Clinical research on similar transcranial magnetic stimulation (TMS) technologies has demonstrated their effectiveness in modulating neuroplasticity, which refers to the brain’s ability to form and reorganize neural connections. EXOMIND builds on these principles, offering a more streamlined and patient-friendly application that can be completed in outpatient settings. The Lamkin Clinic noted that some patients have reported secondary benefits, including reduced food cravings and modest weight loss following a series of six treatments. While not intended as a weight loss solution, these observations point to the therapy’s influence on broader neural circuits tied to reward processing and appetite control.

Why is Lamkin Clinic positioning functional medicine at the center of mental health innovation?

The Lamkin Clinic has long promoted functional medicine as a framework to uncover root causes of chronic conditions rather than simply managing symptoms. Founded by Dr. Brian Lamkin, a board-certified family medicine physician, the clinic emphasizes drug-free approaches aimed at reversing or mitigating health issues through personalized care plans. Its decision to incorporate EXOMIND reflects a growing convergence between functional medicine principles and neuroscience-based interventions for mental health.

Mental health care has historically relied on psychotropic drugs like SSRIs and mood stabilizers, which can be effective but often carry side effects or lose efficacy over time. Functional medicine providers argue that addressing biochemical imbalances, inflammation, hormonal disruptions, and lifestyle factors can yield more sustainable improvements. By adopting EXOMIND, The Lamkin Clinic is positioning itself at the forefront of this integrative model, offering a technology that directly modulates brain activity while patients also receive nutritional, hormonal, and lifestyle interventions to support long-term wellness.

Industry analysts have noted a broader trend of mental health providers adopting neuromodulation tools as demand grows for non-pharmacological options. Rising rates of depression, anxiety, and treatment-resistant mood disorders have spurred innovation, and EXOMIND joins a wave of next-generation brain stimulation devices competing for clinical adoption in the U.S. market.

What other advanced wellness treatments is Lamkin Clinic offering alongside EXOMIND?

While EXOMIND represents the clinic’s most recent technological addition, The Lamkin Clinic has built a reputation for offering a diverse range of cutting-edge therapies aimed at whole-body recovery. These include growth hormone optimization programs, biotoxin illness treatments, medical weight loss plans, thyroid optimization strategies, platelet-rich plasma therapy for tissue regeneration, and interventions for incontinence and pelvic health. Each of these programs aligns with the clinic’s commitment to addressing underlying dysfunctions that often manifest as chronic health complaints.

On the aesthetic and physical performance front, the clinic also offers Emsculpt NEO, a noninvasive procedure combining high-intensity muscle stimulation with targeted radiofrequency heating to build muscle and reduce fat simultaneously. This therapy has been reported to improve back pain, joint stability, and overall mobility by enhancing core strength, which is a key determinant of musculoskeletal resilience. Similarly, Emface and Exion are available for patients seeking facial rejuvenation. These treatments use synchronized radiofrequency and electromagnetic stimulation to tighten skin, reduce wrinkles, lift facial contours, and even plump lips by rebuilding underlying facial muscle tone.

Collectively, these offerings position The Lamkin Clinic as a hybrid wellness center that straddles the line between medical and aesthetic care, catering to patients seeking both functional restoration and enhanced vitality. The addition of EXOMIND expands its scope further into the realm of mental health, which has traditionally been siloed from physical and aesthetic treatments despite strong interconnections between mental and physical well-being.

How could EXOMIND adoption influence Oklahoma’s mental health care landscape?

Oklahoma has long struggled with higher-than-average rates of depression, anxiety, and suicide compared to national benchmarks, which has intensified calls for innovative treatment models. Traditional psychiatry services in the region often face long wait times and limited availability, especially in rural areas. By offering EXOMIND, The Lamkin Clinic is giving local patients access to a therapy that bypasses the need for prescription drugs and could be delivered on a more flexible schedule than psychotherapy or medication management.

Healthcare analysts see this move as part of a broader decentralization of mental health services. Instead of being confined to hospitals or psychiatric practices, new neuromodulation therapies like EXOMIND are being offered in wellness clinics and outpatient functional medicine centers. This shift could reduce stigma, improve treatment access, and normalize the idea of brain-based interventions for emotional health. If early results at The Lamkin Clinic are positive, it may encourage other providers in the state to adopt similar approaches, ultimately broadening the care ecosystem for mood disorders in Oklahoma.

The clinic’s decision to host a Functional Medicine Event on September 25 is also a strategic effort to engage the public and demystify these therapies. Attendees will be able to learn about EXOMIND and other treatments firsthand, potentially accelerating word-of-mouth adoption. Industry experts suggest that public education is a critical barrier for novel mental health technologies, as many patients are unfamiliar with neuromodulation or may mistakenly conflate it with electroconvulsive therapy (ECT), which uses much higher energy levels and is primarily reserved for severe, treatment-resistant depression under anesthesia. By clarifying these distinctions, The Lamkin Clinic could build trust and drive early adoption.

Could EXOMIND signal a shift toward preventive and performance-based brain health models?

While EXOMIND is currently cleared by the U.S. Food and Drug Administration for depression treatment, functional medicine practitioners increasingly view neuromodulation as a potential preventive tool. As mental performance and cognitive resilience become prized assets in both professional and personal life, devices like EXOMIND could eventually find a place in wellness programs designed to enhance focus, regulate stress, and sustain energy levels.

Some market watchers anticipate a convergence between mental health care and biohacking trends, where brain stimulation is paired with lifestyle optimization protocols, nootropics, and hormonal therapies. If The Lamkin Clinic’s integration of EXOMIND proves commercially and clinically successful, it may set a precedent for other functional medicine practices to expand into brain performance optimization—a space currently dominated by wellness startups in major urban markets.

The EXOMIND launch underscores the broader evolution of mental health from a reactive to a proactive paradigm. Instead of waiting for patients to meet the diagnostic thresholds for depression or anxiety, clinics could use these tools to maintain neurological balance and emotional stability before crises occur. While this approach would require careful regulatory oversight and clinical validation, it highlights the shifting mindset shaping next-generation mental wellness care.